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Introduction 
Diabetes mellitus is the most prevalent long term metabolic condition. Diabetes mellitus is a 
multisystem disorder that is characterised by chronic hyperglycaemia. It can be classified 
into the following general categories [1]: 
1. Type 1 diabetes mellitus. This is due to β-cell destruction and usually leads to 
absolute insulin deficiency; 
2. Type 2 diabetes mellitus. This is due to a progressive insulin secretory defect 
coupled with insulin resistance; 
3. Gestational diabetes mellitus. This is diabetes diagnosed during pregnancy that may 
or may not resolve after delivery; 
4. Other. This covers all the conditions that may predispose to hyperglycaemia e.g. 
diseases of the pancreas, glucocorticoid use, and monogenic disorders causing 
maturity onset diabetes of the young.  
There are recent data to suggest that there are several different sub-classes of diabetes [2]. 
However, there are currently not enough data on peri-operative diabetes care to understand 
the implications of these subtypes on the outcomes of surgery.  
 
The prevalence of diabetes is increasing. The most recent estimates from the International 
Diabetes Federation suggest that the number of people worldwide who have diabetes 
mellitus is about 425 million, i.e. 1 in 11 adults. This number is predicted to rise to almost 
700 million by 2045 [3]. Over 90% of these people have type 2 diabetes mellitus. In the UK it 
is estimated that there are 3.8 million people with diabetes (8.6% of the adult population), 
this includes an estimated 940,000 people who have undiagnosed diabetes [4]. Diabetes 
accounts for up to 10% of heath care expenditure in developed nations, and these huge 
costs are related in part to the excess number of hospital admissions [5]. People with 
diabetes (both diagnosed and undiagnosed) have: a significantly longer hospital length of 
stay; more major complications ; a higher requirement for post-operative critical care 
admission;  a higher requirement for post-operative ventilation; and higher mortality rates 
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and episode costs compared to people without diabetes admitted for the same conditions 
[6,7]. In surgical patients, the length of hospital stay is up to 45% higher than those without 
diabetes, with general surgical and orthopaedic patients often having the longest lengths of 
stay [5,8]. In addition, a significant proportion of patients with diabetes mellitus are often 
inappropriately denied day case surgery and this may contribute to the increased length of 
stay [9]. The mortality of surgical patients with diabetes is twice that of those without [10]; 
some of the causes for this are shown in Table 1. There is now increasing evidence that 
diabetes is a modifiable risk factor and that the care of the surgical patient with diabetes and 
pre-diabetes can be optimised, with a subsequent decrease in complications and mortality. It 
is therefore imperative that a consultation request by primary care for a surgical opinion 
mentions diabetes in the referral letter; a recent study showed that the presence of diabetes 
was not included in over 22% of all referral letters for people with the condition [11].  
 
Pre-diabetes and Undiagnosed diabetes 
 
Pre-diabetes is the disorder where there is hyperglycaemia without the accepted criteria for 
diabetes and is seen as precursor to diabetes. Pre-diabetes is diagnosed by either: a 
marginally elevated glycated haemoglobin (HbA1c) concentration; an impaired fasting 
glycaemia; or an impaired glucose tolerance. The diagnostic criteria for prediabetes do not 
describe the same populations, but they do overlap [12]. Depending on the organisation, the 
definitions are different. Table 2 shows the two most widely used criteria – from WHO and 
American Diabetic Association (ADA) for the diagnosis of diagnosis diabetes and pre-
diabetes.  
It is worth explaining the significance of glycated haemoglobin. Glycated haemoglobin 
reflects the average plasma glucose levels that the haemoglobin molecule has been 
exposed to over the preceding three months. It is used to diagnose diabetes and 
prediabetes, and to measure response to treatment. In 2011, the International Federation of 
Clinical Chemistry and Laboratory Medicine (IFCC) units (mmol.mol-1) became the 
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universally accepted units; the Diabetes Control and Complications Trial (DCCT) unit (%) is 
still in use despite being outmoded. 
 
Undiagnosed diabetes is the condition in which the patient has diabetes but is yet to be 
diagnosed. The International Diabetes Federation currently estimates that worldwide just 
over 210 million people have undiagnosed diabetes. [3]. This represents half of all people 
with diabetes. In the United Kingdom, in 2014 Public Health England estimated that the 
prevalence (95%CI) of pre-diabetes in the general population was 10.7% (10.2–11.1%); the 
prevalence (95%CI) of undiagnosed diabetes was 2.3% (2.1–2.6%); and the prevalence 
(95%CI) of diagnosed diabetes was 5.2% (4.9–5.5%) [13]. Despite this, the National Institute 
for Health and Care Excellence does not currently recommend screening for diabetes in the 
‘at risk’ surgical population [14]. This is despite there being evidence to suggest that 
undiagnosed diabetes mellitus is a greater risk factor for harm than diagnosed diabetes 
mellitus in the surgical population [10,15]. It has been argued that this is a missed 
opportunity to improve surgical outcomes [16].  
In a recently published single centre Australian prospective study of patients aged >54 years 
undergoing inpatient surgery, it was demonstrated that of 7565 patients, 2047 (27%) patients 
had diabetes, as defined as HbA1c>48 mmol.mol-1 (6.5%); 2825 (37%) had pre-diabetes, as 
defined as a HbA1c of 39-47 mmol.mol-1 (5.7%-6.4%), and only 2457 (32%) patients were 
normoglycaemic. In addition, 2825 patients were diagnosed with pre-diabetes, and 236 
patients (3% of the total study population) were found to have undiagnosed diabetes mellitus 
[7].  
Table 3 shows a list of characteristics that should lead to a person to being screened for 
diabetes before referral for surgery. If any person is found to have undiagnosed diabetes 
mellitus, the appropriate treatment should be commenced. It is recommended that people 
with type 2 diabetes mellitus have treatment commenced or increased if the HbA1c exceeds 
58 mmol.mol-1 (7.5%), whether surgery is planned or not [17].  
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Diabetes and surgical outcome 
There are data from several surgical specialities to show that poor pre-operative glycaemic 
control (defined as either elevated blood glucose or HbA1c concentrations) is associated 
with harm [7,18-25]. However, increasingly data have suggested that it is those people who 
have previously undiagnosed hyperglycaemia who have the worst outcomes [10,15,26]. It 
may well be that this is because a known diagnosis of diabetes will almost always mean that 
a health care professional will observe and monitor the patient more often,  if only to have a 
bedside capillary glucose measurement taken, and at such time, it may be noticed if the 
patient is becoming more unwell. This is described in a recent study that showed that the 
higher the pre-operative HbA1c, the more frequently capillary glucose concentrations were 
measured, as well as a greater likelihood of going onto an intravenous insulin infusion [27]. If 
an individual’s glycaemic status is not known, they are likely to be observed less often.  
There is work to show poor surgical outcomes occur when the HbA1c concentration is 
raised, but still within the non-diabetic range; this association begins 43 mmol/mol (6.0%) 
[28,29]. There are however currently no prospective studies examining surgical outcome 
after randomising patients with poor glycaemic control to either no diabetes treatment or to 
diabetes treatment. In addition, this study may never occur as it may be deemed unethical to 
randomise patients with diabetes to no treatment. Thus, whilst it may seem ‘intuitive’ to 
optimise pre-operative HbA1c concentrations, there are few data to support this [30]. The 
exceptions to this are cardiac and liver transplant surgery [31,32]. There are also data to 
support improving glucose control to reduce surgical site infections [33]. 
 
Pre-operative glycaemic optimisation 
Given that the epidemiological data suggest that ‘good’ pre-operative  glycaemic control is 
associated with a lower risk of post-operative complications, it has been advocated that 
HbA1c concentrations should be optimised prior to an elective procedure, if it is safe to do so 
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[34]. For some patients, the risk of iatrogenic hypoglycaemia outweighs the benefits of better 
glycaemic control and pre-operative optimisation is not safely possible. For practical reasons 
suggestions from the UK advocate postponement of elective surgery only if the HbA1c is ≥ 
69 mmol.mol-1 (8.5%) [34]; whilst the US Society for Ambulatory Anesthesia (SAMBA) 
suggests 53 mmol.mol-1 (7.0%) [35]. The National Institute for Health and Care Excellence 
now suggest that an HbA1c is a vital test that should be offered to all patients with diabetes if 
it has not been performed in the three months prior to the anticipated date of surgery [14]. 
Data from the Peri-operative Quality Improvement Programme (PQIP) 2017-2018 annual 
report demonstrated that, despite a pre-operative  HbA1c being recommended  in all 
patients with known diabetes, only 69% of such patients in that study had the pre-operative  
HbA1c performed [36].  
Review of glycaemic control, and any subsequent glycaemic optimisation, should commence 
at the time of the referral for a surgical consultation and should continue at all stages of the 
patient journey: primary care; surgical outpatients; pre-operative assessment clinic; hospital 
admission; theatres and recovery; postoperative ward; and discharge home [34]. At all of 
these stages communication between the relevant staff and the patient is vital to help to 
ensure that optimal glycaemic control is achieved and maintained. Pre-operative glycaemic 
optimisation should be facilitated by either primary care or hospital specialists [34].  
 
Pre-operative optimisation of comorbidity and drug therapy 
Diabetes is a multisystem disease and is associated with several other comorbidities. These 
most frequently include cardiovascular disease, peripheral vascular disease, renal disease, 
hypertension, and obesity; 90% of adults with type 2 diabetes aged 16-54 years are 
overweight or obese [37]. Many of these co-existing conditions are also associated with 
increased surgical complications, and there is substantial evidence that patients with less 
severe comorbidity have better outcomes than those with severe and uncontrolled co-
morbidity [38]. In addition, there is now emerging evidence that pre-operative optimisation of 
these associated conditions can lead to an improvement in outcome; many are discussed in 
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detail in other sections of this journal supplement. Furthermore, the peri-operative strategies 
that are used to manage the associated conditions are changing and are associated with 
less morbidity. For example, The BRIDGE trial demonstrated that peri-procedural 
interruption of warfarin, for atrial fibrillation, with no anticoagulant bridging was not inferior to 
low molecular heparin bridging for the prevention of arterial thromboembolism, but 
decreased the risk of peri-procedural major bleeding [39].  
 
The National Institute for Health and Care Excellence has produced many clinical guidelines 
for the optimisation of diabetes and its associated conditions [14,17,40-44]. However it is 
being increasingly realised that these guidelines often only consider the disease in isolation. 
This has the unintended consequence of potentially causing either drug-disease interactions 
or drug-drug interactions if medical practitioners apply the recommendations from the 
guidelines in isolation and do not consider the co-existing morbidity and polypharmacy. Pre-
operative optimisation of the surgical patient with diabetes therefore demands careful 
scrutiny and optimisation/rationalisation of the existing medication to reduce the potential of 
peri-operative adverse drug events including: hypotension; bleeding; bradycardia; ventricular 
arrhythmias; altered plasma concentrations and hypo/hyperkalaemia caused by drug-
disease or drug-drug interactions [45].  
 
Prevention of peri-operative dysglycaemia 
It has been demonstrated that both peri-operative hypoglycaemia and hyperglycaemia are 
associated with harm and death. Hypoglycaemia is often defined as a capillary blood 
glucose <4.0 mmol.l-1 and severe hypoglycaemia is defined as a capillary blood glucose 
<3.0 mmol.l-1 [46]. There are now data to demonstrate that hospital length of stay and 
increased risk of death actually occurs with a capillary blood glucose ≤4.0 mmol.l-1 [47,48]. In 
addition, studies in which tight glycaemic control (4.5-6.0 mmol.l-1) using intensive insulin 
therapy has been compared with a liberal target of 8.0-10.0 mmol.l-1 have showed increased 
harm in the former group [49]. Therefore, the UK peri-operative guidelines now recommend 
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that the lowest acceptable peri-operative capillary blood glucose on those with glucose 
lowering medication should be 6.0 mmol.l-1, with the US guidelines suggesting 
reconsideration of treatment at 5.6 mmol.l-1 [5,34,50]. Because of the data suggesting that 
the treatment for hyperglycaemia is associated with harm, many societies and guidelines 
suggest treating inpatient hyperglycaemia only once the capillary blood glucose is above 
10.0 mmol.l-1 [5,34,50]. Thus, there is a universal consensus that the optimal peri-operative 
target zone is approximately 6.0-10.0 mmol.l-1 [5,34,50-52]. This target is almost identical to 
the range recommended by Alberti in 1979, who suggested 5.0-10.0 mmol.l-1 [53]. In 
addition, the UK guidance recognises the dangers of glucose lowering medication and 
suggests that an upper limit of 12.0 mmol.l-1 may be acceptable [34]. 
As well hyperglycaemia predisposing the patient to both infective and non-infective 
complications, the patient with type 1 diabetes mellitus is also prone to diabetic ketoacidosis. 
Hospital-acquired diabetic ketoacidosis is defined as a patient developing diabetic 
ketoacidosis once in hospital for another reason, makes up almost 8% of all cases of 
diabetic ketoacidosis, and is the thus its third commonest cause [54]. At present the exact 
incidence of hospital acquired diabetic ketoacidosis in the surgical population is unknown. It 
is anticipated that the current National Confidential Enquiry into Patient Outcome and Death 
will be able to provide more data. The UK guidelines suggest the continuation of basal 
insulin, albeit at a reduced dose to prevent this highly undesirable complication [34,50]. 
In addition to identifying patients with previously undiagnosed hyperglycaemia, there are 
several strategies to prevent peri-operative dysglycaemia. These are summarised in Table 4. 
Precise details on the exact implementation of these strategies are beyond the scope of this 
article but have been previously published [50]. 
The unifying aspect for the successful implementation of all of these strategies is meticulous 
pre-operative assessment by staff with expertise in the pre-operative management of 
diabetes. Effective communication with the patient and the ward staff on the chosen 
management plan is vital. The diabetes drugs must be safely prescribed, and to facilitate 
safe day of surgery admission, it is recommended that these drugs are prescribed in the pre-
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operative assessment clinic. In addition, treatment in the event of both hypoglycaemia and 
hyperglycaemia should be prescribed at the per-operative assessment clinic, so that  
dysglycaemia can be managed if required from the moment of hospital admission 
 
Safe use of insulin  
Insulin remains one of the most frequently mis-prescribed and mis-administered drugs [55]. 
These medication errors include the wrong dose; or at the wrong time; or an inappropriate 
omission of a dose. It remains important to prescribe the correctly named insulin. Insulin 
should be prescribed by the complete brand name – including the strength and origin (e.g. 
human, animal or analogue). Importantly, the word ‘unit’ should be written out in full, never 
abbreviated as ‘u’ [56]. The mode of administration should also be included – prefilled pen, 
needle and vial or cartridge. When in doubt, always ask for help from the diabetes team. 
Furthermore, when insulin is administered it should always be given using an insulin syringe 
– these allow for 1 unit increments to be given. 
 
Unresolved issues 
In this section we will deal with the topic of stress hyperglycaemia before looking ahead to 
the future of peri-operative diabetic management.  
The term stress hyperglycaemia describes transient elevations in blood glucose in patients 
without a history of diabetes that occur during acute illness or stress [57]. Several 
observational studies have reported higher morbidity and mortality in surgical patients with 
newly-recognised hyperglycaemia when compared to those even with known diabetes 
[58,59]. In general surgery, the development of peri-operative hyperglycaemia is associated 
with up to a fourfold increase in complications and twice the risk of death compared to 
patients maintaining normoglycaemia;  this risk begins with a capillary blood glucose ≥ 7.8 
mmol.l-1 [10]. In a recent US study, the incidence of stress hyperglycaemia was found to be 
21%; there are currently no studies from the UK [60]. It is currently unknown whether it is the 
patients with prediabetes that develop stress hyperglycaemia. If this was the case, it would 
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further strengthen the argument for pre-operative screening using HbA1c for all patients 
having major surgery. At present there are no pre-/peri-operative studies examining whether 
these patients can be identified or whether treatment can affect the outcome of stress 
hyperglycaemia. The work by Van den Berghe et al in critically ill patients suggests that 
amongst other strategies insulin therapy may have a role, but more work is required [61,62]. 
 
The future remains full of potential in the field of peri-operative glycaemic control. Data from 
the 2017-2018 Peri-operative Quality Improvement Programme showed that, amongst those 
participating hospitals, care of surgical patients with diabetes can be improved, and has 
been identified as the foremost national improvement opportunity for 2018-2019. [36]. These 
data show that diabetes is taking a more prominent position in peri-operative care than 
previously.  
Although there are outcome studies currently going on in this area (e.g. the Optimising 
Cardiac Surgery ouTcomes in People with diabeteS (OCTOPus) trial – HTA project number 
16/25/12 – Professor Richard Holt, personal communication), there remain few data on the 
outcomes and effects of intervention on those not known to have diabetes. Given the rising 
prevalence of obesity this is an important ‘missing link’ in the field. 
There also needs to be more research about the epidemiology of stress hyperglycaemia, 
and its optimal treatment. The optimal agents/ strategies needed to prevent peri-operative 
dysglycaemia also remain to be determined. The ideal agents would not cause 
hypoglycaemia and would be safe to use at times of acute illness. The use of the sodium 
glucose co-transporter 2 inhibitors is associated with an increased risk of diabetic 
ketoacidosis and should be avoided during periods of acute illness and there continues to be 
concerns about the use of metformin in renal impairment. The peri-operative use of drugs 
acting on the incretin pathway, the dipeptidyl peptidase 4 inhibitors and the glucagon-like 
peptides, have shown promise in preventing peri-operative hyperglycaemia;  however, their 
use may be limited by side effects, including nausea and vomiting [63]. Finally, the 
increasing use of technology may help to reduce the risk of dysglycaemia associated with 
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insulin use, as well as reducing the impact on staff time. The use of ‘closed loop’ glucose 
sensors and insulin delivery devices has shown promise in early trials in the inpatient 
population [64-66]. However, because of the difficulties of individualising the algorithms and 
how they change with the changing situation in the hospitalised patient, this technology 
remains some way from routine clinical use.  
 
Implications for practice 
It has become increasingly apparent from the success of enhanced recovery partnership 
programmes that better outcomes are achieved by having a patient pathway that 
commences at primary care referral. This pathway is summarised in Figure 1. Management 
of the surgical patient with diabetes is no different. For the reasons stated, at the time of 
initial referral, the diabetes and other co-morbidities should have been optimised where it is 
safe to do so. The referral letter to the surgical team should detail all relevant pathology and 
medication as well as the current HbA1c. Currently, this is poorly done [11]. If the diabetes is 
not optimally managed at the time of referral, advice from the diabetes team should be 
sought as soon as possible, to facilitate optimisation. Optimisation generally takes about 
three months. Identifying poorly controlled or undiagnosed diabetes at a pre-operative clinic 
just before elective surgery, especially if the referral was made several weeks or months 
previously, should no longer be acceptable.  
Patients should be advised on how to manage their diabetes to facilitate day of surgery 
admission, and day surgery is recommended if the surgery is appropriate. Diabetes is no 
longer a contraindication to day surgery. Day surgery provides less time for iatrogenic 
complications and thus is an integral part of NHS England’s ‘Choosing Wisely’ and ‘Getting it 
Right First Time’ initiatives [67,68]. 
 
Summary 
Peri-operative hyperglycaemia, whether the cause is known diabetes, undiagnosed diabetes 
or stress hyperglycaemia, is a risk factor for harm, increased length of stay and death. There 
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is increasing evidence that peri-operative hyperglycaemia  is a modifiable risk factor, and 
many of the interventions required to improve the outcome of surgery must be instituted prior 
to the actual surgical admission. These interventions depend on the multidisciplinary team 
communicating with each other along each stage of the patient journey and working 
collaboratively for the benefit of the patient and ensuring that integration of care occurs 
across the whole of  the patient centred care pathway. 
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Table 3  Proposal for who should be screened for diabetes prior to referral for surgery. 
 
Table 4  Summary of the various strategies available for peri-operative glycaemic control. 
 
Figure 1  Comprehensive care pathway of the elective surgical patient with diabetes. 
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Table 1. Possible causes of adverse outcomes for surgical patients with diabetes 
mellitus 
 Patients with undiagnosed diabetes 
 Failure to recognise that the surgical patient has diabetes with resultant additional 
requirements 
 Lack of institutional guidelines for management of diabetes 
 Lack of knowledge of diabetes and its management on the part of medical and 
nursing staff 
 Hypoglycaemia and subsequent neuroglycopaenia  
 Multiple co-morbidities including microvascular and macrovascular complications e.g. 
coronary heart disease; renovascular disease; cerebrovascular disease; and 
peripheral vascular disease. 
 Associated obesity in patients with type 2 diabetes 
 Complex polypharmacy for the treatment of the diabetes, including misuse of insulin 
 Complex polypharmacy for the treatment of the co-existing morbidity  
 Inappropriate use of intravenous insulin 
 Electrolyte and fluid disturbances associated with the use of intravenous insulin and 
the coupled fluids  
 Management errors when converting from usual medication to intravenous insulin 
and back to usual medication 
 Hyperglycaemia resulting in peri-operative infection (surgical site  or systemic e.g. 
lower respiratory tract infection, urinary tract infection) 
 Hyperglycaemia resulting in systemic complications e.g. acute coronary syndromes; 
acute kidney injury; and cerebrovascular events 
 Hospital-acquired diabetic ketoacidosis 
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Table 2  The WHO and ADA diagnostic criteria for the different types of dysglycaemia [3].  
 
 Diabetes ‘Prediabetes’ 
  
HbA1c diagnosed 
prediabetes 
Impaired 
fasting 
glucose 
Impaired 
glucose 
tolerance 
HbA1c criteria.  
IFCC units (DCCT 
%) 
≥48 mmol.mol-1   
(≥to 6.5%) 
or 
≥43 - ≤47 
mmol.mol-1   
(6.0-6.4%) 
  
Random glucose 
>11.1 mmol.l-1  
or 
   
Fasting plasma 
glucose 
≥7.0 mmol.l-1   
or 
 
6.1 - 6.9 
mmol.l-1    
 
<7.0 mmol.l-1   
and 
Two-hour plasma 
glucose following a 
75g oral glucose 
load 
 
≥11.1 mmol.l-1  
 
  
≥7.8 -  <11.1 
mmol.l-1  
 
* These criteria are included in the term ‘pre-diabetes’. IFCC, International Federation of 
Clinical Chemistry; WHO, World Health Organisation; ADA, American Diabetes Association 
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Table 3  Proposal for who should be screened for diabetes prior to referral for 
surgery. 
 
 Aged >40 years old (>30 years in people of South Asian origin) 
 Family history of diabetes 
 Personal history of gestational diabetes 
 Personal history of hypertension 
 Personal history of dyslipidaemia 
 Personal history of prediabetes 
 Body Mass Index (BMI) >25 kg.m-2 (23 kg.m-2 in those of South Asian origin) 
 Those on long term glucocorticoid treatment 
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Table 4  Summary of the strategies available for peri-operative glycaemic control. 
 
Strategy 
Pre-requisite 
requirement 
Advantages Disadvantages 
No changes 
Diet controlled T2DM 
with an HbA1c<8.5% 
Minimal risk of iatrogenic 
complications 
Will not control additional 
stress hyperglycaemia 
Modification 
of normal 
glucose 
lowering 
medication 
 Adequately 
controlled DM with 
a pre-existing 
HbA1c <8.5% 
 Short starvation 
period (<1 missed 
meal) 
 Patient able to 
understand 
instructions on 
how to modify 
normal medicines 
Simple 
effective 
 Not suitable for prolonged 
starvation 
 Some of the drugs are 
contra-indicated in the 
peri-operative period 
Initiation of 
basal insulin 
with 
correction 
dose insulin  
 T2DM  on oral 
hypoglycaemic 
agents T2DM on 
oral 
hypoglycaemic 
agents  
 Short starvation 
period ( <1 missed 
meal) 
 
Overcomes the concern 
that the product data 
sheets  of some oral 
hypoglycaemic agents 
suggest discontinuation 
in the peri-operative 
period 
 Need to be seen by a 
diabetes  specialist to 
facilitate safe transfer from 
oral hypoglycaemic agents 
 All the intrinsic risks of 
insulin prescription and 
administration 
Continuation 
of continuous 
subcutaneous 
insulin 
infusion (CSII) 
 Normally on CSII 
 Short starvation 
period ( <1 missed 
meal) 
 Patient able to 
understand 
instructions on 
how to modify 
CSII 
Minimal disruption to 
normal diabetes 
management 
 Lack of familiarity by staff 
 Pump manufactures now 
suggesting avoidance of 
use in the presence of 
diathermy 
Variable rate 
intravenous 
insulin 
infusion 
(VRIII) 
 Dedicated 
cannula 
 Ability for staff to 
safely establish 
the VRIII with 
associated fluid 
 Ability for staff to 
check CBG hourly 
 Ability for staff to 
establish and 
discontinue VRIII 
safely 
 Needs two pumps 
 
Theoretically has the 
ability to achieve the best 
degree of glycaemic 
control 
 Lack of hourly checking of 
CBG predisposes to 
hypoglycaemia/ 
hyperglycaemia. 
 Issues with initiation and 
discontinuation can 
predispose to DKA 
 Choice of substrate fluid 
may predispose to 
electrolyte imbalance. 
 Difficult to use in day 
surgery 
Glucose-  Simple and relatively  Wasteful due to need to 
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Insulin 
Potassium 
(GIK) infusion 
safe 
Effective absorption as 
administered 
intravenously. 
Only needs 1 pump 
replace whole fluid bag if 
CBG falls out of target 
zone. 
 Will need additional fluids 
to prevent electrolyte 
imbalance 
‘Sliding scale’ 
subcutaneous 
insulin 
boluses 
 Simple 
 Does not prevent 
dysglycaemia 
 Discredited and not 
recommended 
 
CBG, capillary blood glucose; DKA, diabetic ketoacidosis; DM, diabetes mellitus; CSII, 
continuous subcutaneous insulin infusion; T2DM, type 2 diabetes mellitus; VRIII, variable 
rate intravenous insulin infusion.  
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Figure 1  Comprehensive care pathway of the elective surgical patient with diabetes  
 
 
 
 
 
  
 
 
